Demand for Fluoro Enzymatic Assays Rising as Adoption of Immunoassay And Immunoassay Products Increases: Fact.MR

Increasing incidence of chronic diseases is fuelling the demand for fluorescence-activated sorters and laser-induced fluorescence probes, enabling growth in fluoro enzymatic assays market

According to Fact.MR’s ongoing study on the global fluoro enzymatic assays market, rising cases of infectious diseases such as neurological disorders, hepatitis, dengue, cancer and AIDS are anticipated to drive the demand of fluoro enzymatic assays. Leading players are increasing the research & development (R&D) activities for developing and introducing technologically advanced kits and novel devices for detection of antibodies. For instance, Bio-Rad Laboratories Inc., on 7th April 2021, launched a blood-based immunoassay kit to identify antibodies to the coronavirus SARS-CoV-2.

Furthermore, adoption of advanced technology of immunoassay and immunoassay products is propelling the growth of fluoro enzymatic assays. Chronic diseases such as diabetes, cardiovascular diseases, and cancer are improving the adoption of immunoassays kits/products across the globe. According to the report The Burden of Cancer in the United States by National Cancer Institute states, in 2020, around 1,806,590 cancer cases were recorded in United States and around 606,520 cases were recorded as fatal. Acknowledging this burden, medical professionals have increased their funding and investment for the development of immunoassays kit/instrument for the early detection and diagnosis of the antibodies. Thereby, improving the demand.

Request a report sample to gain comprehensive insights at

“Some of the leading manufacturers are incorporating advanced technology and increasing their investment in the development of fluoro immunoassays kits/products for the treatment of various chronic diseases. This, will in turn, create growth opportunities for the market,” says the Fact.MR analyst.

Key Takeaways

  • Oncology segment is expected to be the fastest growing segment in the global fluoro enzymatic assays market
  • United States will be the most dominant country leading the North America market backed by the advanced healthcare industry and increasing adoption of technologically advanced medical devices
  • Countries such as India, China and South Korea are expected to lead the growth in Asia Pacific owing to the increased healthcare expenditure in the region
  • Dearth of skilled professionals and trainers in GCC countries will be a major restraining factor for the fluoro enzymatic assays market across Middle East & Africa
  • In terms of products, reagents and kits are expected to emerge as a potential segment through 2021
  • Hospitals and Biotech companies are expected to be the primary end-users for the fluoro enzymatic assays market

Prominent Drivers

  • Technological advancements in automation of immunoassays and rising demand for safer reagents will improve the demand of fluoro enzymatic assays
  • Improved timing, accuracy, and precision in detecting sensitivity are some of the advantages that will likely boost the growth
  • Rising prevalence of chronic diseases such as cancer, AIDS and more is driving the demand for fluoro enzymatic assays

Key Restraints

  • Inadequate reimbursement in underdeveloped economies and lack of awareness about the treatment will likely hamper the market growth
  • Low detection limits and lack of diagnostic tools in some regions is expected to restrict the demand

Discover more about the fluoro enzymatic assays market with figures, data tables and the table of contents.

Competitive Landscape

Key manufacturers operating in the global fluoro enzymatic assays market include Becton Dickinson and Company, Siemens Healthineers, BioMerieuxx, Abbott Laboratories, Danaher Corporation, Roche Diagnostics, Ortho Clinical Diagnostics, Thermo Fisher Scientific Inc., Sysmex Corporation, and Quidel Corporation among others. Fact.MR forecasts, as the market is highly fragmented, introducing new treatment approaches and developing effective drugs/kits to combat infections are the key growth strategies adopted by the aforementioned players.

For instance, on February 18th 2021, Agilent Technologies Inc., announced the launch of Agilent Dako SARS-CoV-2, IgG Enzyme-Linked immunosorbent assay kit developed for the qualitative detection of immunoglobulin G antibodies to SARS-CoV-2 in human serum or plasma.

Also, in April 2021, BioMerieux, a world leader in the field of in vitro diagnostics, announced the CE marking of its innovative and fully-automated assays to diagnose dengue infection namely: VIDAS® DENGUE NS1 Ag, VIDAS® Anti-DENGUE IgM, and VIDAS® Anti-DENGUE IgG.

Furthermore, key players are investing heavily in research & development to develop new product kits & drugs for the treatment of various cancer type. For instance, Roche Diagnostics, on 14th April 2021, announced the launch of Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies to aid diagnosis of various cancer types

Get Customization on this Report for Specific Research Solutions

More Insights on the Fluoro enzymatic assays Market Report

In its latest report, Fact.MR offers unbiased analysis of the global fluoro enzymatic assays market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (analyzers/instruments, reagents & kits, and software & services), application (oncology, cardiology, infectious diseases, bone & mineral, toxicology, autoimmunity, endocrinology, neonatal screening, and hematology), end-user (hospitals, academics, laboratories, pharmaceutical industries, CRO’s and biotech), across seven regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa)

Explore Fact.MR’s Coverage on the Healthcare Domain

Chemiluminescence immunoassay Market: Fact.MR’s exclusive coverage on the global chemiluminescence immunoassay market sheds light on the prominent expansion dynamics likely to play a pivotal role in furthering future growth. A detailed segment-wise and regional assessment has been embedded within the scope of this study, along with an exhaustive profiling of prominent microscopy device manufacturers present in the landscape.

Immunoassay Market: An extensive study by Fact.MR on the global immunoassay market, analyses crucial trends which determine future expansion prospects of the landscape. Details regarding prominent manufacturers and segments across prominent regions have also been provided in this study.

Cancer Immunotherapy market: A detailed assessment of cancer immunotherapy market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in Fact.MR’s coverage on the landscape. A comprehensive estimate on cancer immunotherapy market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of cancer immunotherapy market during the forecast period.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Follow Us: LinkedIn | Twitter
Source: Fact.MR

Back to news